A First-time-in-human Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Ascending Doses of GSK189075A in Healthy Subjects and in Subjects With Type 2 Diabetes Mellitus

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

September 30, 2004

Primary Completion Date

January 31, 2005

Study Completion Date

January 31, 2005

Conditions

Diabetes Mellitus, Type 2

Interventions

DRUG

GSK189075A

20mg, 50mg, 150mg, 500mg, 1000mg or Placebo

OTHER

Placebo